Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy

被引：38

作者：

Castagna, Luca ^{[1
]}

Bramanti, Stefania ^{[1
]}

Balzarotti, Monica ^{[1
]}

Sarina, Barbara ^{[1
]}

Todisco, Elisabetta ^{[1
]}

Anastasia, Antonella ^{[1
]}

Magagnoli, Massimo ^{[1
]}

Mazza, Rita ^{[1
]}

Nozza, Andrea ^{[1
]}

Giordano, Laura ^{[2
]}

Rodari, Marcello ^{[4
]}

Rinifilo, Eva ^{[3
]}

Chiti, Arturo ^{[4
]}

Santoro, Armando ^{[1
]}

机构：

[1] Ist Clin Humanitas, Dept Haematol & Oncol, Rozzano, MI, Italy

[2] Ist Clin Humanitas, Stat Unit, Rozzano, MI, Italy

[3] Ist Clin Humanitas, Dept Radiol, Rozzano, MI, Italy

[4] Ist Clin Humanitas, Dept Nucl Med, Rozzano, MI, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 145卷 / 03期

关键词：

Hodgkin lymphoma; haemopoietic stem cell transplantation; positron emission tomography; PROGNOSTIC VALUE; 18-FLUORODEOXYGLUCOSE; PRETRANSPLANTATION; THERAPY; REGIMEN; RELAPSE; DISEASE;

D O I：

10.1111/j.1365-2141.2009.07645.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P < 0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.

引用

页码：369 / 372

页数：4

共 13 条

[1] Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation [J].

Becherer, A ;

Mitterbauer, M ;

Jaeger, U ;

Kalhs, P ;

Greinix, HT ;

Karanikas, G ;

Pötzi, C ;

Raderer, M ;

Dudczak, R ;

Kletter, K .

LEUKEMIA, 2002, 16 (02) :260-267

[2] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[3] Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy:: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial [J].

Fermé, C ;

Mounier, N ;

Diviné, M ;

Brice, P ;

Stamatoullas, A ;

Reman, O ;

Voillat, L ;

Jaubert, J ;

Lederlin, P ;

Colin, P ;

Berger, F ;

Salles, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :467-475

[4] The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation [J].

Filmont, Jean-Emmanuel ;

Gisselbrecht, Christian ;

Cuenca, Xavier ;

Deville, Laure ;

Ertault, Marjan ;

Brice, Pauline ;

De Kerviler, Eric ;

Briere, Josette ;

Larghero, Jerome ;

Moretti, Jean-Luc ;

Mounier, Nicolas .

CANCER, 2007, 110 (06) :1361-1369

[5]

Gallamini A, 2006, HAEMATOLOGICA, V91, P475

[6] Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma [J].

Jabbour, Elias ;

Hosing, Chitra ;

Ayers, Gregory ;

Nunez, Rodolfo ;

Anderlini, Paolo ;

Pro, Barbara ;

Khouri, Issa ;

Younes, Anas ;

Hagerneister, Fredrick ;

Kwak, Larry ;

Fayad, Luis .

CANCER, 2007, 109 (12) :2481-2489

[7] New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group [J].

Josting, A ;

Franklin, J ;

May, M ;

Koch, P ;

Beykirch, MK ;

Heinz, J ;

Rudolph, C ;

Diehl, V ;

Engert, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :221-230

[8] IGEV regimen and a xed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients [J].

Magagnoli, M. ;

Spina, M. ;

Balzarotti, M. ;

Timofeeva, I. ;

Isa, L. ;

Michelli, M. ;

Capizzuto, R. ;

MOrenghi, E. ;

Castagna, L. ;

Tirelli, U. ;

Santoro, A. .

BONE MARROW TRANSPLANTATION, 2007, 40 (11) :1019-1025

[9] Ifosfamide, gemcitabine, and vinorelbine: a now induction regimen for refractory and relapsed Hodgkin's lymphoma [J].

Santoro, Armando ;

Magagnoli, Massimo ;

Spina, Michele ;

Pinotti, Graziella ;

Siracusano, Licia ;

Michieli, Mariagrazia ;

Nozza, Andrea ;

Sarina, Barbara ;

Morenghi, Emanuela ;

Castagna, Luca ;

Tirelli, Umberto ;

Balzarotti, Monica .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01) :35-41

[10] Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial [J].

Schmitz, N ;

Pfistner, B ;

Sextro, M ;

Sieber, M ;

Carella, AM ;

Haenel, M ;

Boissevain, F ;

Zschaber, R ;

Müller, P ;

Kirchner, H ;

Lohri, A ;

Decker, S ;

Koch, B ;

Hasenclever, D ;

Goldstone, AH ;

Diehl, V .

LANCET, 2002, 359 (9323) :2065-2071

← 1 2 →